Expression of interleukin-8 in primary and metastatic malignant melanoma of the skin

Melanoma Research

Volumn 9, Issue 4, 1999, Pages 383-387

  Singh, R K ^a   Varney, M L ^a   Bucana, C D ^b   Johansson, S L ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Interleukin 8; Melanoma; Metastasis

Indexed keywords

INTERLEUKIN 8;

ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE DISTRIBUTION;

EID: 0032871384     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199908000-00007     Document Type: Article

References (29)

1. 1. Lee JAH. The current rapid increase in incidence of mortality from malignant melanoma in developed societies. Pigment Cell 1976; 2: 414-420.
2. 2. Clark WH, Elder DE, Guerry D, et al. Study of tumor progression: the precursor lesions of superficial spreading melanoma and nodular melanoma. Hum Pathol 1984; 15: 1147-1165.
3. 3. Franceschi S, La Vecchia C, Lucchini F, et al. The epidemiology of cutaneous malignant melanoma: etiology and European data. Eur J Cancer Prevention 1991; 1: 9-22.
4. 4. Elwood JM, Koh HK. Etiology, epidemiology, risk factors, and public health issues of melanoma. Curr Opin Oncol 1994; 6: 179-187.
5. 5. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics 1998. CA Cancer J Clin 1998; 48: 6-30.
6. 6. Herlyn M. Human melanoma: development and progression. Cancer Metastasis Rev 1990; 9: 101 112.
7. 7. Kerbel RS. Growth dominance of metastatic cancer cells: cellular and molecular aspects. Adv Cancer Res 1990; 55: 87-133.
8. 8. Balch CM, Cascinelli N, Milton GW, et al. Surgical decisions regarding lymph node dissection for stage I melanoma patients: pros and cons of immediate vs. delayed lymphadenectomy. In: Balch CM, Milton GW, eds. Cutaneous Melanoma: Clinical Management and Treatment Results. Philadelphia: J. B. Lippincott, 1985: 188-200.
9. 9. Fidler IJ, Radinsky R. Search for genes that suppress cancer metastasis. J Natl Cancer Inst 1996; 88: 1700 1703.
10. 10. Herlyn D, Iliopoulos D, Jensen PJ, et al. In vitro properties of human melanoma cells metastatic in nude mouse. Cancer Res 1990; 50: 2296-2302.
11. 11. Herlyn M, Kath R, Williams N, et al. Growth regulatory factors for normal premalignant human cells in vivo. Adv Cancer Res 1990; 54: 213-234.
12. 12. Singh RK, Gutman M, Radinsky R, et al. Expression of interleukin-8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 1994; 54: 3242-3247.
13. 13. Schandendorf D, Moller A, Algermissen B, Worm M, et al. IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol 1993; 151: 2667-2675.
14. 14. Koch AE, Folverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258: 1798-1801.
15. 15. Strieter RM, Kunkel SL, Elner VM, et al. Interleukin-8: a corneal factor that induces neovascularization. Am J Pathol 1992; 141: 1279-1284.
16. 16. Wang JM, Taraboletti G, Matsushima K, et al. Induction of hematopoietic migration of melanoma cells by neutrophil activating protein/IL-8. Biochem Biophys Res Commun 1990; 169: 165-170.
17. 17. Scheibenbogen C, Mohler T, Haefele J, et al. Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour load. Melanoma Res 1995; 5: 179-181.
18. 18. Ishiko T, Sakamoto K, Yamashita S-I, et al. Carcinoma cells express IL-8 and the IL-8 receptor: their inhibition attenuates the growth of carcinoma cells. Int J Oncol 1995; 6: 119-122.
19. 19. Smith DR, Polverini Pj, Kunkel SL, et al. Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J Exp Med 1994; 179: 1409-1415.
20. 20. Clark W. Tumor progression and the nature of cancer. Br J Cancer 1991; 64: 631-644.
21. 21. Gutman M, Singh RK, Radinsky R, Bar-Eli M, Intertumoral heterogeneity of receptor-tyrosine kinases expression in human melanoma cell lines with different metastatic capabilities. Anticancer Res 1994; 14: 1759-1766.
22. 22. Guerry D, Synnestvedt M, Elder DE, et al. Lesson from tumor progression: the invasive radial growth phase of melanoma is common and incapable of metastasis and indolent. J Invest Dermatol 1993; 100: 342-345.
23. 23. Matsushima K, Oppenheim J. Interleukin-8 and MCAF: novel inflammatory cytokines inducible by IL-1 and TNF. Cytokine 1989; 1: 2-13.
24. 24. Zachariae COC, Thestug-Pedersen K, Matsushima K. Expression and secretion of leukocyte chemotactic cytokines by normal human melanocytes and melanoma cells, J Invest Dermatol 1991; 97: 593-599.
25. 25. Bani MR, Rak J, Adachi D, et al. Multiple features of advanced melanoma recapitulated in tumorigenic variants of early stage (radial growth phase) human melanoma cell lines: evidence for a dominant phenotype. Cancer Res 1996; 56: 3075-3086.
26. 26. Schadendorf D, Fichtner I, Makki A, et al. Metastatic potential of human melanoma cells in nude mice -characterization of phenotype, cytokine secretion, and tumor associated antigens. Br J Cancer 1996; 74: 194-199.
27. 27. Tilg H, Shapiro L, Lee TH, et al. Induction of circulating and erythrocyte bound IL-8 by IL.-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonists and soluble tumor necrosis factor (p75) chimera. J Immunol 1993; 151: 4687-4692.
28. 28. Singh RK, Gutman M, Reich R, Bar-Eli M. UV-B irradiation promotes tumorigenic and metastatic properties in primary cutaneous melanoma via induction of IL-8. Cancer Res 1995; 55: 3669-3671.
29. 29. Gimbrone MA Jr, Obin MS, Brock AF, et al. IL-8: a novel inhibitor of leukocyte-endothelial interaction. Science 1989; 246: 1601-1604.